Active Ingredient(s):Lorlatinib FDA Approved: * November 2, 2018 Pharm Company: *PFIZER INC Category:Cancer
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.
1 Medical uses
3 Side effects
5.1 Mechanism of action
7.1 Clinical studies
* May have multiple approval dates, manufacturers, or labelers.